Literature DB >> 27275100

Ulcerative colitis patients in clinical remission demonstrate correlations between fecal immunochemical test results, mucosal healing, and risk of relapse.

Asuka Nakarai1, Jun Kato1, Sakiko Hiraoka1, Shiho Takashima1, Daisuke Takei1, Toshihiro Inokuchi1, Yuusaku Sugihara1, Masahiro Takahara1, Keita Harada1, Hiroyuki Okada1.   

Abstract

AIM: To assess the risk of relapse in ulcerative colitis (UC) patients in clinical remission using mucosal status and fecal immunochemical test (FIT) results.
METHODS: The clinical outcomes of 194 UC patients in clinical remission who underwent colonoscopy were based on evaluations of Mayo endoscopic subscores (MESs) and FIT results.
RESULTS: Patients with an MES of 0 (n = 94, 48%) showed a ten-fold lower risk of relapse than those with an MES of 1-3 (n = 100, 52%) (HR = 0.10, 95%CI: 0.05-0.19). A negative FIT result (fecal hemoglobin concentrations ≤ 100 ng/mL) was predictive of patients with an MES of 0, with a sensitivity of 0.94 and a specific of 0.76. Moreover, patients with a negative FIT score had a six-fold lower risk of clinical relapse than those with a positive score (HR = 0.17, 95%CI: 0.10-0.28). Inclusion of the distinguishing parameter, sustaining clinical remission > 12 mo, resulted in an even stronger correlation between negative FIT results and an MES of 0 with respect to the risk of clinical relapse (HR = 0.11, 95%CI: 0.04-0.23).
CONCLUSION: Negative FIT results one year or more after remission induction correlate with complete mucosal healing (MES 0) and better prognosis. Performing FIT one year after remission induction may be useful for evaluating relapse risk.

Entities:  

Keywords:  Clinical remission; Mayo endoscopic subscore; Mucosal healing; Quantitative fecal immunochemical test; Ulcerative colitis

Mesh:

Substances:

Year:  2016        PMID: 27275100      PMCID: PMC4886383          DOI: 10.3748/wjg.v22.i21.5079

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  26 in total

1.  Prognosis of ulcerative colitis differs between patients with complete and partial mucosal healing, which can be predicted from the platelet count.

Authors:  Asuka Nakarai; Jun Kato; Sakiko Hiraoka; Toshihiro Inokuchi; Daisuke Takei; Yuki Moritou; Mitsuhiro Akita; Sakuma Takahashi; Keisuke Hori; Keita Harada; Hiroyuki Okada; Kazuhide Yamamoto
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

Review 2.  Mucosal healing in inflammatory bowel diseases: a systematic review.

Authors:  Markus F Neurath; Simon P L Travis
Journal:  Gut       Date:  2012-07-27       Impact factor: 23.059

3.  A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis.

Authors:  Triana Lobatón; Francisco Rodríguez-Moranta; Alicia Lopez; Elena Sánchez; Lorena Rodríguez-Alonso; Jordi Guardiola
Journal:  Inflamm Bowel Dis       Date:  2013-04       Impact factor: 5.325

4.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.

Authors:  K W Schroeder; W J Tremaine; D M Ilstrup
Journal:  N Engl J Med       Date:  1987-12-24       Impact factor: 91.245

5.  Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease.

Authors:  J A Tibble; G Sigthorsson; S Bridger; M K Fagerhol; I Bjarnason
Journal:  Gastroenterology       Date:  2000-07       Impact factor: 22.682

6.  A quantitative immunochemical fecal occult blood test for colorectal neoplasia.

Authors:  Zohar Levi; Paul Rozen; Rachel Hazazi; Alex Vilkin; Amal Waked; Eran Maoz; Shlomo Birkenfeld; Moshe Leshno; Yaron Niv
Journal:  Ann Intern Med       Date:  2007-02-20       Impact factor: 25.391

7.  Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes.

Authors:  Alain M Schoepfer; Christoph Beglinger; Alex Straumann; Ekaterina Safroneeva; Yvonne Romero; David Armstrong; Carsten Schmidt; Michael Trummler; Valérie Pittet; Stephan R Vavricka
Journal:  Inflamm Bowel Dis       Date:  2013-02       Impact factor: 5.325

8.  Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission.

Authors:  Jordi Guardiola; Triana Lobatón; Lorena Rodríguez-Alonso; Alexandra Ruiz-Cerulla; Claudia Arajol; Carolina Loayza; Xavier Sanjuan; Elena Sánchez; Francisco Rodríguez-Moranta
Journal:  Clin Gastroenterol Hepatol       Date:  2014-06-30       Impact factor: 11.382

9.  Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.

Authors:  Stephane Nancey; Gilles Boschetti; Driffa Moussata; Eddy Cotte; Julie Peyras; Charlotte Cuerq; Julie Haybrard; Anne-Laure Charlois; Anne Mialon; Marion Chauvenet; Karine Stroeymeyt; Dominique Kaiserlian; Jocelyne Drai; Bernard Flourié
Journal:  Inflamm Bowel Dis       Date:  2013-04       Impact factor: 5.325

10.  Clinical Study of the Relation between Mucosal Healing and Long-Term Outcomes in Ulcerative Colitis.

Authors:  Kaoru Yokoyama; Kiyonori Kobayashi; Miyuki Mukae; Miwa Sada; Wasaburo Koizumi
Journal:  Gastroenterol Res Pract       Date:  2013-05-09       Impact factor: 2.260

View more
  6 in total

1.  Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients With Ulcerative Colitis: A Systematic Review and Meta-Analysis.

Authors:  Hyuk Yoon; Sushrut Jangi; Parambir S Dulai; Brigid S Boland; Larry J Prokop; Vipul Jairath; Brian G Feagan; William J Sandborn; Siddharth Singh
Journal:  Gastroenterology       Date:  2020-06-22       Impact factor: 22.682

2.  Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing.

Authors:  Sushrut Jangi; Hyuk Yoon; Parambir S Dulai; Mark Valasek; Brigid S Boland; Vipul Jairath; Brian G Feagan; William J Sandborn; Siddharth Singh
Journal:  Aliment Pharmacol Ther       Date:  2020-08-09       Impact factor: 8.171

Review 3.  The Value of Fecal Markers in Predicting Relapse in Inflammatory Bowel Diseases.

Authors:  Bianca J Galgut; Daniel A Lemberg; Andrew S Day; Steven T Leach
Journal:  Front Pediatr       Date:  2018-01-19       Impact factor: 3.418

4.  A Light-Weight Practical Framework for Feces Detection and Trait Recognition.

Authors:  Lu Leng; Ziyuan Yang; Cheonshik Kim; Yue Zhang
Journal:  Sensors (Basel)       Date:  2020-05-06       Impact factor: 3.576

5.  Clinical Significance of Residual Nonrectal Inflammation in Ulcerative Colitis Patients in Clinical Remission.

Authors:  Jongbeom Shin; Sung Min Kong; Tae Jun Kim; Eun Ran Kim; Sung Noh Hong; Dong Kyung Chang; Young-Ho Kim
Journal:  Gut Liver       Date:  2021-05-15       Impact factor: 4.519

Review 6.  Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease.

Authors:  Kohei Wagatsuma; Yoshihiro Yokoyama; Hiroshi Nakase
Journal:  Life (Basel)       Date:  2021-12-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.